Chiesi Keen To Nurture Disruptive Innovation

Italian Group Raising International Profile

Chiesi may not be a big pharma giant but it is very good at spotting early-stage innovative projects and partnering with the likes of Moderna, Protalix and Bioasis to tackle respiratory and rare diseases, CEO Ugo Di Francesco tells Scrip.

Parma
Parma is home to Chiesi • Source: Alamy

The recent rejection in the US for its Fabry disease drug pegunigalsidase alfa partnered with Protalix BioTherapeutics, Inc. was clearly a setback for Chiesi Farmaceutici S.p.A. but the Italian company has a number of other partnerships that will help the company continue its strategy of becoming a major player in respiratory and rare diseases on a global scale.

Founded in 1935 in Parma by entrepreneurial chemist Giacomo Chiesi, the company has been best known for steadily building its expertise in Italy and the rest of Europe in the respiratory field

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

More from Scrip

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By 

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pharma Left Hanging After US/UK Trade Pact

 
• By 

An ‘historic economic prosperity deal’ does not include the sector.